Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Systematic Review Article

Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis

Author(s): Wenfang Guo, Xue Gong and Minhui Li*

Volume 25 , Issue 28 , 2019

Page: [3087 - 3095] Pages: 9

DOI: 10.2174/1381612825666190829153552

Price: $65

Abstract

Background: The lipid profile is associated with metabolic diseases in overweight and obese individuals. Quercetin treatment is suggested to reduce the risk factors for obesity.

Objective: The aim of the literature meta-analysis was to determine the range of doses of quercetin administration on plasma lipid levels in overweight and obese human subjects.

Methods: Articles searched on EMBASE, PubMed, Cochrane Library, and Web of Science through March 20, 2019, were reviewed independently using predetermined selection criteria. The Cochrane collaboration’s tool for assessing risk of bias was used to assess the quality of the included trials. Heterogeneity was measured using Cochran's Q test and the I-square (I2) statistic. Data were pooled using a random-effects model and the standardized mean difference (SMD) was considered for measuring the overall effect size.

Results: Of 176 articles reviewed, 9 randomized clinical trials were selected based on the inclusion criteria. The pooled results for the effect of quercetin administration on LDL-cholesterol (SMD: -002; 95% CI: -0.15–0.11), HDL-cholesterol (SMD: -0.06; 95% CI: -0.19–0.07), triglycerides (SMD: 0.05; 95% CI: -0.08–0.18), and total cholesterol (SMD: 0.04; 95% CI: -0.09–0.17) were not significantly different from the control group results. Quercetin administration at doses of ≥250 mg/day (SMD: -0.58 ; 95% CI: -0.94–-0.22) and total dose ≥14,000 mg (SMD: -0.58 ; 95% CI: -0.94–-0.22) significantly reduced LDL levels; however, HDL-cholesterol, triglycerides, and total cholesterol levels remained unchanged (p > 0.05).

Conclusion: Quercetin administration does not affect plasma lipid levels in overweight and obese individuals. However, it significantly reduces LDL-cholesterol levels at doses of ≥250 mg/day and total dose ≥14000 mg.

Keywords: Quercetin, lipid profiles, overweight, obesity, meta-analysis, cholesterol.

[1]
Williams EP, Mesidor M, Winters K, Dubbert PM, Wyatt SB. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep 2015; 4(3): 363-70.
[http://dx.doi.org/10.1007/s13679-015-0169-4] [PMID: 26627494]
[2]
WHO. Obesity and Overweight fact sheet from the WHO Retrieved December 13, 2018, from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[3]
World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
[PMID: 11234459]
[4]
Fujimoto WY, Bergstrom RW, Boyko EJ, Leonetti DL, Newell-Morris LL, Wahl PW. Susceptibility to development of central adiposity among populations. Obes Res 1995; 3(Suppl. 2): 179S-86S.
[http://dx.doi.org/10.1002/j.1550-8528.1995.tb00461.x] [PMID: 8581774]
[5]
Bouchard C, Bray GA, Hubbard VS. Basic and clinical aspects of regional fat distribution. Am J Clin Nutr 1990; 52(5): 946-50.
[http://dx.doi.org/10.1093/ajcn/52.5.946] [PMID: 2239774]
[6]
Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: Effect on patients’ risk. Obes Res 1998; 6(Suppl. 1): 8S-17S.
[http://dx.doi.org/10.1002/j.1550-8528.1998.tb00683.x] [PMID: 9569171]
[7]
Albu JB, Kovera AJ, Johnson JA. Fat distribution and health in obesity. Ann N Y Acad Sci 2000; 904: 491-501.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb06505.x] [PMID: 10865794]
[8]
Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995; 3(Suppl. 2): 187S-94S.
[http://dx.doi.org/10.1002/j.1550-8528.1995.tb00462.x] [PMID: 8581775]
[9]
Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4): 1381-478.
[http://dx.doi.org/10.1152/physrev.00047.2003] [PMID: 15383655]
[10]
Zimmermann-Belsing T, Feldt-Rasmussen U. Obesity: The new worldwide epidemic threat to general health and our complete lack of effective treatment. Endocrinology 2004; 145(4): 1501-2.
[http://dx.doi.org/10.1210/en.2004-0078] [PMID: 15026374]
[11]
Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: Systematic review. Int J Obes 2011; 35(7): 891-8.
[http://dx.doi.org/10.1038/ijo.2010.222] [PMID: 20975725]
[12]
Maningat P, Breslow JL. Needed: Pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011; 365(24): 2250-1.
[http://dx.doi.org/10.1056/NEJMp1112023] [PMID: 22085320]
[13]
Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: A common dilemma not reflected in clinical trials. Cleve Clin J Med 2011; 78(6): 393-403.
[http://dx.doi.org/10.3949/ccjm.78a.10073] [PMID: 21632911]
[14]
Harper CR, Jacobson TA. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18(4): 401-8.
[http://dx.doi.org/10.1097/MOL.0b013e32825a6773] [PMID: 17620856]
[15]
Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8(6): 373-418.
[http://dx.doi.org/10.2165/0129784-200808060-00004] [PMID: 19159124]
[16]
Sharifi N, Tabrizi R, Moosazadeh M, et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des 2018; 24(23): 2729-42.
[http://dx.doi.org/10.2174/1381612824666180406104516] [PMID: 29623830]
[17]
Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013; 35(8): 1082-98.
[http://dx.doi.org/10.1016/j.clinthera.2013.06.019] [PMID: 23932550]
[18]
Akbari M, Ostadmohammadi V, Lankarani KB, et al. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Metabolism 2018; 87: 56-69.
[http://dx.doi.org/10.1016/j.metabol.2018.07.002] [PMID: 29990473]
[19]
Zhao Y, Chen B, Shen J, et al. The beneficial effects of quercetin, curcumin, and resveratrol in obesity. Oxid Med Cell Longev 2017; 20171459497
[http://dx.doi.org/10.1155/2017/1459497] [PMID: 29138673]
[20]
Neha K, Haider MR, Pathak A, Yar MS. Medicinal prospects of antioxidants: A review. Eur J Med Chem 2019; 178: 687-704.
[http://dx.doi.org/10.1016/j.ejmech.2019.06.010] [PMID: 31228811]
[21]
Kim JK, Park SU. Quercetin and its role in biological functions: An updated review. EXCLI J 2018; 17: 856-63.
[PMID: 30233284]
[22]
Wang X, Ouyang YY, Liu J, Zhao G. Flavonoid intake and risk of CVD: A systematic review and meta-analysis of prospective cohort studies. Br J Nutr 2014; 111(1): 1-11.
[http://dx.doi.org/10.1017/S000711451300278X] [PMID: 23953879]
[23]
Khorshidi M, Moini A, Alipoor E, et al. The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome. Phytother Res 2018; 32(11): 2282-9.
[http://dx.doi.org/10.1002/ptr.6166] [PMID: 30062709]
[24]
Lee JS, Cha YJ, Lee KH, Yim JE. Onion peel extract reduces the percentage of body fat in overweight and obese subjects: A 12-week, randomized, double-blind, placebo-controlled study. Nutr Res Pract 2016; 10(2): 175-81.
[http://dx.doi.org/10.4162/nrp.2016.10.2.175] [PMID: 27087901]
[25]
Zhang M, Xie Z, Gao W, Pu L, Wei J, Guo C. Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats. Nutr Res 2016; 36(3): 271-9.
[http://dx.doi.org/10.1016/j.nutres.2015.11.019] [PMID: 26923514]
[26]
Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008; 16(9): 2081-7.
[http://dx.doi.org/10.1038/oby.2008.315] [PMID: 18551111]
[27]
Brüll V, Burak C, Stoffel-Wagner B, et al. Acute intake of quercetin from onion skin extract does not influence postprandial blood pressure and endothelial function in overweight-to-obese adults with hypertension: A randomized, double-blind, placebo-controlled, crossover trial. Eur J Nutr 2017; 56(3): 1347-57.
[http://dx.doi.org/10.1007/s00394-016-1185-1] [PMID: 26924303]
[28]
Brüll V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: A randomised double-blinded placebo-controlled cross-over trial. Br J Nutr 2015; 114(8): 1263-77.
[http://dx.doi.org/10.1017/S0007114515002950] [PMID: 26328470]
[29]
Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr Metab Cardiovasc Dis 2013; 23(5): 403-9.
[http://dx.doi.org/10.1016/j.numecd.2011.08.010] [PMID: 22118955]
[30]
Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010; 140(2): 278-84.
[http://dx.doi.org/10.3945/jn.109.117655] [PMID: 20032478]
[31]
Sahebkar A. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 2017; 57(4): 666-76.
[http://dx.doi.org/10.1080/10408398.2014.948609] [PMID: 25897620]
[32]
Lu TM, Chiu HF, Shen YC, Chung CC, Venkatakrishnan K, Wang CK. Hypocholesterolemic efficacy of quercetin rich onion juice in healthy mild hypercholesterolemic adults: A pilot study. Plant Foods Hum Nutr 2015; 70(4): 395-400.
[http://dx.doi.org/10.1007/s11130-015-0507-4] [PMID: 26385226]
[33]
Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br J Nutr 2009; 102(7): 1065-74.
[http://dx.doi.org/10.1017/S0007114509359127] [PMID: 19402938]
[34]
Mazloom Z, Abdollahzadeh SM, Dabbaghmanesh MH, Rezaianzadeh A. The effect of quercetin supplementation on oxidative stress, glycemic control, lipid profile and insulin resistance in type 2 diabetes: A randomized clinical trial. J Health Sci Surveillance Sys 2014; 2(1): 8-14.
[35]
Choi EY, Lee H, Woo JS, et al. Effect of onion peel extract on endothelial function and endothelial progenitor cells in overweight and obese individuals. Nutrition 2015; 31(9): 1131-5.
[http://dx.doi.org/10.1016/j.nut.2015.04.020] [PMID: 26233871]
[36]
Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007; 137(11): 2405-11.
[http://dx.doi.org/10.1093/jn/137.11.2405] [PMID: 17951477]
[37]
Jeong SM, Kang MJ, Choi HN, Kim JH, Kim JI. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr Res Pract 2012; 6(3): 201-7.
[http://dx.doi.org/10.4162/nrp.2012.6.3.201] [PMID: 22808343]
[38]
Zhao L, Wu J, Wang Y, et al. Cholesterol metabolism is modulated by quercetin in rats. J Agric Food Chem 2011; 59(4): 1104-8.
[http://dx.doi.org/10.1021/jf1035367] [PMID: 21250691]
[39]
Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem Toxicol 2013; 52: 53-60.
[http://dx.doi.org/10.1016/j.fct.2012.10.030] [PMID: 23123425]
[40]
de Boer VC, van Schothorst EM, Dihal AA, et al. Chronic quercetin exposure affects fatty acid catabolism in rat lung. Cell Mol Life Sci 2006; 63(23): 2847-58.
[http://dx.doi.org/10.1007/s00018-006-6316-z] [PMID: 17103110]
[41]
Liu L, Gao C, Yao P, Gong Z. Quercetin alleviates high-fat diet-induced oxidized low-density lipoprotein accumulation in the liver: Implication for autophagy regulation. BioMed Res Int 2015; 2015607531
[http://dx.doi.org/10.1155/2015/607531] [PMID: 26697490]
[42]
Chang YC, Lee TS, Chiang AN. Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages. J Lipid Res 2012; 53(9): 1840-50.
[http://dx.doi.org/10.1194/jlr.M024471] [PMID: 22711909]
[43]
Mariee AD, Abd-Allah GM, El-Beshbishy HA. Protective effect of dietary flavonoid quercetin against lipemic-oxidative hepatic injury in hypercholesterolemic rats. Pharm Biol 2012; 50(8): 1019-25.
[http://dx.doi.org/10.3109/13880209.2012.655424] [PMID: 22775419]
[44]
Bhaskar S, Kumar KS, Krishnan K, Antony H. Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition 2013; 29(1): 219-29.
[http://dx.doi.org/10.1016/j.nut.2012.01.019] [PMID: 22595451]
[45]
Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res 2018; 62(1)1700447
[http://dx.doi.org/10.1002/mnfr.201700447] [PMID: 29127724]
[46]
Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45(11): 2179-205.
[http://dx.doi.org/10.1016/j.fct.2007.05.015] [PMID: 17698276]
[47]
Stewart LK, Soileau JL, Ribnicky D, et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism 2008; 57(7)(Suppl. 1): S39-46.
[http://dx.doi.org/10.1016/j.metabol.2008.03.003] [PMID: 18555853]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy